Showing results (1281-1290 of 2,691) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|March 8, 2024
A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus studyManu P Bilsen, Simon P Conroy, Caroline Schneeberger, et al.
The Lancet. Infectious Diseases|February 26, 2024
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in AustraliaBhagwat Gunale, Nicholas Farinola, Chandrashekhar D Kamat, et al.
The Lancet. Infectious Diseases|November 9, 2023
Re-visiting humoral constitutive antibacterial heterogeneity in bloodstream infectionsRyuichiro Abe, Nikhil Ram-Mohan, Samuel Yang
The Lancet. Infectious Diseases|October 26, 2023
Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccinesAlexandra Trkola, Penny L Moore
The Lancet. Infectious Diseases|July 27, 2023
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trialIssaka Sagara, Sara A Healy, Mahamadoun H Assadou, et al.
The Lancet. Infectious Diseases|July 21, 2023
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort studyAlberto Mateo-Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, et al.
The Lancet. Infectious Diseases|August 13, 2023
Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasyYara-Natalie Abo, Euzebiusz Jamrozik, James S McCarthy, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
The Lancet. Infectious Diseases|September 25, 2023
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysisRobert J Commons, Megha Rajasekhar, Peta Edler, et al.
Pageof 270